Valvular & structural heart diseaseMeta-analysis
Women in the Leadership of Interventional Structural Heart Disease Trials
- systematic review and meta-analysis
- random-effects meta-analysis
- generalized linear mixed-effects meta-regression
Authors' conclusion
Women remain markedly under-represented in the leadership and authorship of interventional SHD trials, with no significant improvement over time. Deliberate efforts and policies to improve diversity in trial leadership may help address downstream inequities in cardiovascular evidence generation.
Study context
- Population
- Interventional structural heart disease trials published in high-impact journals between 2010 and 2025
- Participants
- 88 eligible trials
Pooled result
As reported in the abstract
Steering committee reported
Trials reporting a steering committee
67.8%
Trials providing committee member names
55.8%
Further pooled results
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Temporal trend in women's representation on committees · did not increase significantly over time | 1.02 (0.93–1.12) | P = 0.70 | |
| Temporal trend in women as committee chair | 1.41 (1.05–2.34) | P = 0.075 | |
| 0.512Odds ratio (log scale) |
- Temporal trend in women as committee chair: increased numerically but did not reach statistical significance
Women's representation on committees (among trials with available committee membership)
- Committee seats held by women
- 7.0%
- Committees composed entirely of men
- 56.2%
Women as committee chair and senior author
- Trials with a woman as committee chair
- 12.0%
- Publications with a woman as senior author
- 14.0%
Original publication
Women in the Leadership of Interventional Structural Heart Disease Trials. JACC Adv. Published 27 July 2026. doi:10.1016/j.jacadv.2026.103073
Summarised from the published abstract; every number is checked against it